AVAILABILITY ANALYSIS OF ORAL ANTIPLATELETS IN THE RUSSIAN FEDERATION

Abstract The Aim. Pharmacoeconomic assessment of the oral antiplatelet availability of various drug manufacturers and dosage forms based on the analysis of price characteristics. Materials and methods. The analysis included drugs from the group of platelet aggregation inhibitors (excluding heparin) (ATC code B01AC): clopidogrel, clopidogrel + acetylsalicylic acid (ASA), ASA and dipyridamole in various dosages and number of tablets per package. The cost values were estimated by the resources of large resources "Apteka.ru", "009.rf" with the average value calculations in the eight federal district’s capitals of the country. Results. The cost of drugs in the analyzed group varied depending on the drug manufacturer. The highest amount of the cost variation was in the ASA tablet form (100 mg) – 407.47%, followed by the tablet form of clopidogrel (75 mg) – 311.16%, ASA (50 mg) – 172.20%, dipyridamole (75 mg) – 117.36% and the lowest values for the tablet forms of dipyridamole (25 mg) – 68.19% and the combination of ASA with clopidogrel (100mg + 75mg) – 59.13%. The highest Ca.s values were in ticagrelor (90 mg) – 24.92% and prasugrel (10 mg) – 7.87%, the lowest in ASA (50 mg) – 0.1%. According to the linear index of distribution, the drugs ASA (100 mg) – 89%, clopidogrel (75 mg) – 70%, and less accessible ticagrelor (60 mg) – 18% and prasugrel (10 mg) – 14% had a higher physical availability. Conclusion. Based on the calculated values a high availability of such antiplatelet drugs as ASA (50 mg and 100 mg), clopidogrel (75 mg) was revealed. According to the results of the study, the antiplatelet drugs ticagrelor (60 mg and 90 mg) and prasugrel (10 mg) have the least level of availability.